[go: up one dir, main page]

US20070254855A1 - Method for the treatment of acne - Google Patents

Method for the treatment of acne Download PDF

Info

Publication number
US20070254855A1
US20070254855A1 US11/776,676 US77667607A US2007254855A1 US 20070254855 A1 US20070254855 A1 US 20070254855A1 US 77667607 A US77667607 A US 77667607A US 2007254855 A1 US2007254855 A1 US 2007254855A1
Authority
US
United States
Prior art keywords
day
oral
antibiotic
acne
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/776,676
Other versions
US20080182826A2 (en
Inventor
Mitchell Wortzman
R. Plott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicis Pharmaceutical Corp
Original Assignee
Medicis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37568356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20070254855(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medicis Pharmaceutical Corp filed Critical Medicis Pharmaceutical Corp
Priority to US11/776,676 priority Critical patent/US20080182826A2/en
Publication of US20070254855A1 publication Critical patent/US20070254855A1/en
Publication of US20080182826A2 publication Critical patent/US20080182826A2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics

Definitions

  • This invention relates to the treatment of acne vulgaris, commonly known simply as “acne.”
  • Acne is a disease of the skin in which the pilosebaceous structures of the skin become inflamed, leading to the formation of comedones, pustules and nodules. Acne can lead to permanent scarring in severe cases.
  • acne arises when hyperkeratosis of the pilosebaceous structure wholly or partially blocks the opening of the structure, resulting in comedones filled with sebum, keratin, and Propionibacterium acnes . These lesions are commonly identified as acne. P. acnes naturally occurs in normal skin, but is especially and characteristically present in acne lesions. It is believed that metabolic byproducts and waste from P. acnes within the pilosebaceous structures cause or contribute to the inflammation of acne lesions.
  • Topical keratolytic agents such as salicylic acid are sometimes used. Keratolytic agents are thought to encourage the opening up of blocked pilosebaceous structures, thereby reducing conditions that are favorable to inflammation. Benzoyl peroxide, an anti-microbial, remains a popular and effective treatment. Topical antibiotics, such as clindamycin, which are effective against P. acnes , have also been used with a view towards preventing the formation of metabolic byproducts from this organism. Topical retinoids such as tretinoin have also been used in the treatment of acne.
  • Systemic (i.e. non-topical) treatments for acne include the use of oral antibiotics in more serious cases. These treatments are directed towards the reduction in the amount P. acnes in the skin, especially the pilosebaceous structures, and seek to reduce the inflammation caused by waste materials and metabolic byproducts from these organisms. Tetracycline antibiotics are most commonly used for this purpose. These include tetracycline, minocycline and doxycycline. Erythromycin is also sometimes used.
  • Standard oral minocycline therapy for acne in pediatric patients calls for the administration of a 4 mg/kg initial loading dose, and a 2 mg/kg dose every 12 hours thereafter. This results in a dose of 6 mg/kg on the first day of treatment and a 4 mg/kg dose each day thereafter. In adults, a 200 mg initial dose is followed by a 100 mg dose every 12 hours thereafter. In a typical patient, this results in about a 4.5 mg/kg dose on the first day of treatment, and 3.0 mg/kg dose each day thereafter.
  • isotretinoin is sometimes used. While effective, isotretinoin is also powerfully teratogenic, and women of childbearing age are required to use multiple methods of contraception while taking the drug.
  • a method for the treatment of acne in which an antibiotically effective dose of an oral tetracycline, such as minocycline, is provided.
  • This dose is approximately 1 milligram per kilogram of body weight (1 mg/kg), without an initial loading dose of antibiotic.
  • This antibiotic dosing regimen has been found to be as effective as a conventional dosing regimen incorporating a significant initial loading dose and higher subsequent doses.
  • the dosing method of the current invention produces far fewer side effects.
  • the oral tetracycline is provided in a dosage form that provides for the continued release of the antibiotic between doses, as opposed to an immediate or nearly immediate release of the drug.
  • acne vulgaris is treated by the use of an oral tetracycline antibiotic, preferably minocycline.
  • This antibiotic is administered in an antibiotically effective amount of approximately 1.0 milligram per kilogram of body weight per day (1.0 mg/kg/day). While this may be accomplished by the use of divided doses, it is preferred that the tetracycline antibiotic be delivered in a single daily dose.
  • This treatment regime is initiated without a loading dose, and is continued until resolution or substantial resolution of the patient's acne.
  • the course of treatment typically lasts 12 to up to 60 weeks, but will be adjusted according to the disease status and other medical conditions of each patient in the exercise of ordinary good clinical judgment by the patient's health care provider.
  • delayed release dosage forms are known in the art, the formulation of them is far from predictable and the selection of a specific delayed release formulation is accomplished more by trial and error than by mathematical prediction based on known properties of delay release agents. No delayed release product useful in the present invention has been known heretofore.
  • the ratio of fast dissolving carriers to slow dissolving carriers in the core caplet is important in obtaining a dissolution profile that enables once-a-day dosing in accordance with the present invention. By keeping the ratio of these components within a certain range, one may obtain this result.
  • the fast dissolving carrier is any binder, vehicle, or excipient that quickly dissolves in an aqueous physiological medium, such as gastric fluid, thereby tending to quickly release the active ingredient. Lactose, its salts and hydrates are good examples of such components. It has been observed that sometimes a portion of the fast dissolving components are formulated in a manner that results in the complete or partial encapsulation or inclusion or coating of these fast-dissolving materials in granules of slow-dissolving materials. These encapsulated materials are excluded from the calculation of the above mentioned ratio of fast-dissolving to slow dissolving components.
  • a slow dissolving carrier is any binder, vehicle, or excipient that dissolves slowly over the course of hours and perhaps a day, thereby slowing the release of the active ingredient.
  • examples of such components are polyvinyl pyrrolidone, polyvinyl acetate, microcrystalline cellulose, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, or waxy or lipid-based tableting agents such as magnesium stearate or calcium stearate.
  • Outer “enteric” coatings are excluded from this amount when calculating the above-mentioned ratio.
  • Insoluble carriers are binders, vehicles, or excipients that are practically insoluble in physiological fluids, such as gastric fluid, and includes compounds, such as silicon dioxide and talc.
  • Dosage forms such as capsules, tablets, and caplets that release 25 to 52% of the antibiotics within 1 hour, 53 to 89% in 2 hours, and at least 90% within 4 hours are suited to the once-a-day dosage regimen contemplated by the current inventories. More preferably, 30 to 52% of the antibiotic is released within 1 hour, 53 to 84% within 2 hours, and at least 85% within 4 hours.
  • the oral tetracycline antibiotic may be delivered in a dosage form that releases the antibiotic in such a way that the maximum blood concentration of the antibiotic (C max ) is reached at about 3.5 hours after administration (T max ).
  • the C max should be reached between 2.75 and 4.0 after administration, more preferably between 3.0 and 3.75 after administration.
  • Each of these components is combined in a conventional fashion, compressed in a tabletting apparatus, and then provided in a conventional manner with a suitable coating, such as, without limitation Opadry II and optional coloring.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 11/166,817 filed on Jun. 24, 2005 the entire disclosure of which is incorporated by reference in its entirety.
    • FIELD OF THE INVENTION
  • This invention relates to the treatment of acne vulgaris, commonly known simply as “acne.” Acne is a disease of the skin in which the pilosebaceous structures of the skin become inflamed, leading to the formation of comedones, pustules and nodules. Acne can lead to permanent scarring in severe cases.
  • It is generally believed that acne arises when hyperkeratosis of the pilosebaceous structure wholly or partially blocks the opening of the structure, resulting in comedones filled with sebum, keratin, and Propionibacterium acnes. These lesions are commonly identified as acne. P. acnes naturally occurs in normal skin, but is especially and characteristically present in acne lesions. It is believed that metabolic byproducts and waste from P. acnes within the pilosebaceous structures cause or contribute to the inflammation of acne lesions.
  • Conventional acne treatments have taken many forms. Topical keratolytic agents, such as salicylic acid are sometimes used. Keratolytic agents are thought to encourage the opening up of blocked pilosebaceous structures, thereby reducing conditions that are favorable to inflammation. Benzoyl peroxide, an anti-microbial, remains a popular and effective treatment. Topical antibiotics, such as clindamycin, which are effective against P. acnes, have also been used with a view towards preventing the formation of metabolic byproducts from this organism. Topical retinoids such as tretinoin have also been used in the treatment of acne.
  • Systemic (i.e. non-topical) treatments for acne include the use of oral antibiotics in more serious cases. These treatments are directed towards the reduction in the amount P. acnes in the skin, especially the pilosebaceous structures, and seek to reduce the inflammation caused by waste materials and metabolic byproducts from these organisms. Tetracycline antibiotics are most commonly used for this purpose. These include tetracycline, minocycline and doxycycline. Erythromycin is also sometimes used.
  • Standard oral minocycline therapy for acne in pediatric patients calls for the administration of a 4 mg/kg initial loading dose, and a 2 mg/kg dose every 12 hours thereafter. This results in a dose of 6 mg/kg on the first day of treatment and a 4 mg/kg dose each day thereafter. In adults, a 200 mg initial dose is followed by a 100 mg dose every 12 hours thereafter. In a typical patient, this results in about a 4.5 mg/kg dose on the first day of treatment, and 3.0 mg/kg dose each day thereafter.
  • In cases where acne does not respond to oral antibiotic treatment, oral isotretinoin is sometimes used. While effective, isotretinoin is also powerfully teratogenic, and women of childbearing age are required to use multiple methods of contraception while taking the drug.
  • While oral tetracycline antibiotics remain a highly favored and widely used treatment for more serious cases of acne, it is not without side effects. Vestibular side effects, including extreme dizziness and concomitant nausea, can be so severe as to result in discontinuance of tetracycline therapy. Long term use can sometimes result in vaginal candidisis, esophageal erosions and in antibiotic resistant infections.
  • Some recent research has indicated that very low doses of oral tetracycline can result in some improvement of acne even though the dose of tetracycline is too low to have an antibiotic effect. This observation has been attributed to an anti-inflammatory effect of tetracycline compounds. This effect has been reported to have been observed even where a chemically modified tetracycline that have no antibiotic properties are used. The use of tetracycline antibiotics at a dose too low to have an antibiotic effect or the use of modified tetracycline having no antibiotic properties as treatments for acne has never been approved by any drug regulatory agency.
    • SUMMARY OF THE INVENTION
  • According to the present invention, a method is provided for the treatment of acne in which an antibiotically effective dose of an oral tetracycline, such as minocycline, is provided. This dose is approximately 1 milligram per kilogram of body weight (1 mg/kg), without an initial loading dose of antibiotic. This antibiotic dosing regimen has been found to be as effective as a conventional dosing regimen incorporating a significant initial loading dose and higher subsequent doses. However, the dosing method of the current invention produces far fewer side effects.
  • In another aspect of this invention, the oral tetracycline is provided in a dosage form that provides for the continued release of the antibiotic between doses, as opposed to an immediate or nearly immediate release of the drug.
    • DETAILED DESCRIPTION OF THE INVENTION
  • According to the present invention, acne vulgaris is treated by the use of an oral tetracycline antibiotic, preferably minocycline. This antibiotic is administered in an antibiotically effective amount of approximately 1.0 milligram per kilogram of body weight per day (1.0 mg/kg/day). While this may be accomplished by the use of divided doses, it is preferred that the tetracycline antibiotic be delivered in a single daily dose. This treatment regime is initiated without a loading dose, and is continued until resolution or substantial resolution of the patient's acne. The course of treatment typically lasts 12 to up to 60 weeks, but will be adjusted according to the disease status and other medical conditions of each patient in the exercise of ordinary good clinical judgment by the patient's health care provider.
  • Controlled, double-blinded studies were undertaken to determine the effectiveness of this invention. Treatment of 473 patients with acne was undertaken according to the present invention. Placebos were provided to 239 patients. The effectiveness of the invention in treating acne vulgaris is shown in Table 1.
    TABLE 1
    Total Lesion Counts
    Total Lesions Total Lesions (as Percent of Baseline)
    Baseline (mean) 169.3 100
    Day 28 (mean) 134.0 78
    Day 56 (mean) 119.3 69
  • TABLE 1
    Total Lesion Counts
    Total Lesions Total Lesions (as Percent of Baseline)
    Day 84 (mean) 112.3 66
  • Inflammatory Lesion Counts
    Inflammatory Inflammatory Lesions (as
    Lesions Percent of Baseline)
    Baseline (mean) 77.4 100
    Day 28 (mean) 52.1 66
    Day 56 (mean) 44.3 56
    Day 84 (mean) 41.9 53
  • While effective as a treatment for acne, this resulted in almost no side effects above those observed with a placebo, as shown in Table 2.
    TABLE 2
    % Subjects with Adverse Events
    Minocycline Placebo
    At least One Adverse Event 56.2 54.1
    At Least One Serious 0.4 0
    Adverse Event
    Blood/Lymphatic System 0.3 0.3
    Disorders
    Cardiac Disorders 0.3 0
    Ear and Labyrinth Disorders 3.6 3.3
    Endocrine Disorders 0.3 0
    Eye Disorders 2.2 2.7
    Gastrointestinal Disorders 21.2 26.1
    General Disorders and 13.8 10.4
    Administrative Site
    Conditions
    Immune System Disorders 0.7 2.5
    Infections and Infestations 9.3 11.0
    Laboratory Blood 0.7 1.1
    Abnormalities
    Metabolism and Nutrition 0.6 0.3
    Disorders
    Musculoskeletal and 4.6 3.6
    Connective Disorders
    Neoplasms Benign, 0.1 0
    Malignant and Unspecified
    Nervous System Disorders 29.2 25.8
    Psychiatric Disorders 6.4 7.1
    Renal and Urinary Disorders 0.3 0.5
    Reproductive System and 0.7 0.3
    Breast Disorders
    Respiratory, Thoracic and 5.3 6.9
    Mediastinal Disorders
    Skin and Subcutaneous 8.6 7.1
    Tissue Disorders
    Vascular Disorders 1.0 0.3
  • The effectiveness of this invention can be seen by comparing the above efficacy data with published data on the effectiveness of conventional tetracycline treatments for acne in the reduction of total acne lesions and in the reduction of inflammatory lesions. See, e.g. Hersel & Gisslen, “Minocycline in Acne Vulgaris: A Double Blind Study,” Current Therapeutic Research, 1976.
  • Because of the variations in body weight encountered in clinical practice, in the actual practice of this invention it is not practical to provide every patient with exactly 1 mg/kg/day of oral tetracycline antibiotic. However, it is acceptable to approximate this dose by providing the patient with from 0.5 to 1.5 mg/kg/day although from 0.7 to 1.3 mg/kg/day is preferred, and 1.0 mg/kg/day is ideal.
  • While it can be effective to provide the oral tetracycline antibiotic in divided doses taken over the course of a day (e.g. twice or three times a day), it is preferable to provide the oral tetracycline antibiotic in a dosage form that releases the antibiotic slowly during the course of a day so that once-a-day dosing is possible. While delayed release dosage forms are known in the art, the formulation of them is far from predictable and the selection of a specific delayed release formulation is accomplished more by trial and error than by mathematical prediction based on known properties of delay release agents. No delayed release product useful in the present invention has been known heretofore.
  • It has been discovered that the ratio of fast dissolving carriers to slow dissolving carriers in the core caplet is important in obtaining a dissolution profile that enables once-a-day dosing in accordance with the present invention. By keeping the ratio of these components within a certain range, one may obtain this result.
  • The fast dissolving carrier is any binder, vehicle, or excipient that quickly dissolves in an aqueous physiological medium, such as gastric fluid, thereby tending to quickly release the active ingredient. Lactose, its salts and hydrates are good examples of such components. It has been observed that sometimes a portion of the fast dissolving components are formulated in a manner that results in the complete or partial encapsulation or inclusion or coating of these fast-dissolving materials in granules of slow-dissolving materials. These encapsulated materials are excluded from the calculation of the above mentioned ratio of fast-dissolving to slow dissolving components.
  • A slow dissolving carrier is any binder, vehicle, or excipient that dissolves slowly over the course of hours and perhaps a day, thereby slowing the release of the active ingredient. Examples of such components are polyvinyl pyrrolidone, polyvinyl acetate, microcrystalline cellulose, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, or waxy or lipid-based tableting agents such as magnesium stearate or calcium stearate. Outer “enteric” coatings are excluded from this amount when calculating the above-mentioned ratio.
  • Insoluble carriers are binders, vehicles, or excipients that are practically insoluble in physiological fluids, such as gastric fluid, and includes compounds, such as silicon dioxide and talc.
  • While the exact formulation of these dosage forms can vary, it has been observed that it is advantageous to formulate them so that the ratio of fast dissolving carriers to slow dissolving carriers is from 0.30 to 0.50, and preferably from 0.35 to 0.45. A ratio of about 0.36 to 0.40 is particularly preferable.
  • Dosage forms, such as capsules, tablets, and caplets that release 25 to 52% of the antibiotics within 1 hour, 53 to 89% in 2 hours, and at least 90% within 4 hours are suited to the once-a-day dosage regimen contemplated by the current inventories. More preferably, 30 to 52% of the antibiotic is released within 1 hour, 53 to 84% within 2 hours, and at least 85% within 4 hours.
  • Alternatively, the oral tetracycline antibiotic may be delivered in a dosage form that releases the antibiotic in such a way that the maximum blood concentration of the antibiotic (Cmax) is reached at about 3.5 hours after administration (Tmax). In actual practice of the invention, the Cmax should be reached between 2.75 and 4.0 after administration, more preferably between 3.0 and 3.75 after administration.
  • As examples of such a once-a-day formulation, one may use the following:
    135 mg Caplet
    Quantity
    Component (mg)
    Minocycline (as 145.8
    hydrochloride)
    (dry weight)
    Lactose 107.4
    Monohydrate
    (intragranular)
    Lactose 43.8
    Monohydrate
    (extragranular)
    Total Lactose 151.2
    Monohydrate
    HPMC 94
    Silicon Dioxide 3
    Mg. Stearate 6
  • 45 mg Caplet
    Quantity
    Component (mg)
    Minocycline (as 48.6
    hydrochloride)
    (dry weight)
    Lactose 192.2
    Monohydrate
    (intragranular)
    Lactose 42.2
    Monohydrate
    (extragranular)
    Total Lactose 234.40
    Monohydrate
    HPMC 108
    Silicon Dioxide 3
    Mg. Stearate 6
  • Each of these components is combined in a conventional fashion, compressed in a tabletting apparatus, and then provided in a conventional manner with a suitable coating, such as, without limitation Opadry II and optional coloring.

Claims (10)

1. A method of treating acne vulgaris, comprising the step of administering to a person suffering from acne vulgaris an oral dosage form comprising:
an oral minocycline antibiotic;
a fast dissolving carrier; and
a slow dissolving carrier;
wherein said oral dosage form is formulated to provide a patient with about 0.5 mg/kg/day to about 1.5 mg/kg/day of said oral minocycline antibiotic;
wherein said fast dissolving carrier and said slow dissolving carrier are at a weight ratio of about 0.3 to about 0.5 of fast dissolving carrier to slow dissolving carrier.
2. The method of claim 1, wherein said oral dosage form is formulated to provide the patient with about 0.7 mg/kg/day to about 1.3 mg/kg/day of said oral minocycline antibiotic.
3. The method of claim 1, wherein said oral dosage form is formulated to provide the patient with about 1.0 mg/kg/day of said oral minocycline antibiotic.
4. The method of claim 1, comprising administering said oral minocycline antibiotic without a loading dose.
5. The method of claim 1, wherein said oral minocycline antibiotic is minocycline as hydrochloride.
6. The method of claim 1, comprising administering said oral minocycline antibiotic once a day.
7. The method of claim 1, wherein said oral dosage form releases said oral minocycline antibiotic in such a manner that said oral minocycline antibiotic reaches a Cmax in the person's blood between about 2.75 hours and about 4.0 hours after administration.
8. The method of claim 7, wherein the Cmax is reached between about 3.0 hours and about 3.75 hours after administration.
9. The method of claim 1, wherein said weight ratio of fast dissolving carrier to slow dissolving carrier in said oral dosage form is from about 0.35 to about 0.45.
10. The method of claim 1, wherein said weight ratio of fast dissolving carrier to slow dissolving carrier in said oral dosage form is from about 0.36 to about 0.40.
US11/776,676 2005-06-24 2007-07-12 Method for the treatment of acne Abandoned US20080182826A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/776,676 US20080182826A2 (en) 2005-06-24 2007-07-12 Method for the treatment of acne

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/166,817 US7919483B2 (en) 2005-06-24 2005-06-24 Method for the treatment of acne
US11/776,676 US20080182826A2 (en) 2005-06-24 2007-07-12 Method for the treatment of acne

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/166,817 Continuation US7919483B2 (en) 2005-06-24 2005-06-24 Method for the treatment of acne

Publications (2)

Publication Number Publication Date
US20070254855A1 true US20070254855A1 (en) 2007-11-01
US20080182826A2 US20080182826A2 (en) 2008-07-31

Family

ID=37568356

Family Applications (6)

Application Number Title Priority Date Filing Date
US11/166,817 Active 2027-03-07 US7919483B2 (en) 2005-06-24 2005-06-24 Method for the treatment of acne
US11/776,669 Abandoned US20080182825A2 (en) 2005-06-24 2007-07-12 Method for the treatment of acne
US11/776,691 Abandoned US20070275933A1 (en) 2005-06-24 2007-07-12 Method for the treatment of acne
US11/776,676 Abandoned US20080182826A2 (en) 2005-06-24 2007-07-12 Method for the treatment of acne
US11/776,711 Abandoned US20080181945A2 (en) 2005-06-24 2007-07-12 Method for the treatment of acne
US11/944,186 Abandoned US20080182827A2 (en) 2005-06-24 2007-11-21 Method for the treatment of acne

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US11/166,817 Active 2027-03-07 US7919483B2 (en) 2005-06-24 2005-06-24 Method for the treatment of acne
US11/776,669 Abandoned US20080182825A2 (en) 2005-06-24 2007-07-12 Method for the treatment of acne
US11/776,691 Abandoned US20070275933A1 (en) 2005-06-24 2007-07-12 Method for the treatment of acne

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/776,711 Abandoned US20080181945A2 (en) 2005-06-24 2007-07-12 Method for the treatment of acne
US11/944,186 Abandoned US20080182827A2 (en) 2005-06-24 2007-11-21 Method for the treatment of acne

Country Status (11)

Country Link
US (6) US7919483B2 (en)
EP (1) EP1898925A4 (en)
JP (2) JP2008543936A (en)
CN (1) CN101208097A (en)
AU (1) AU2006262428B2 (en)
CA (1) CA2613273C (en)
IL (1) IL188331A0 (en)
NO (1) NO20080444L (en)
NZ (1) NZ564093A (en)
WO (1) WO2007001961A2 (en)
ZA (1) ZA200802064B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080070872A1 (en) * 2005-06-24 2008-03-20 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20080241241A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20090041846A1 (en) * 2005-06-24 2009-02-12 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US9192615B2 (en) 2008-08-06 2015-11-24 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110092677A1 (en) * 2001-08-30 2011-04-21 Biorexis Technology, Inc. Modified transferin-antibody fusion proteins
CN1893956A (en) 2003-07-25 2007-01-10 沃纳奇尔科特公司 Doxycycline metal complex solid dosage form
ES2588584T3 (en) * 2005-01-21 2016-11-03 Warner Chilcott Company, Llc A metal tetracycline complex in a solid dosage form
US20080241235A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20100215744A1 (en) * 2008-08-06 2010-08-26 Medicis Pharmaceutical Corporation Hydroxypropyl Substitution Used to Regulate Dissolution of a Chemical
US7544373B2 (en) * 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7541347B2 (en) * 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
CN101678108A (en) * 2007-03-23 2010-03-24 分子研究中心公司 Anti-inflammatory compositions comprising tetracyclines and uses thereof
WO2008121107A1 (en) * 2007-04-02 2008-10-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080241197A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline dosage forms for the treatment of acne
US20120027855A1 (en) * 2007-07-06 2012-02-02 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
WO2012153884A1 (en) * 2011-05-12 2012-11-15 (주)아모레퍼시픽 Composition having improved stability for ameliorating acne
EP4268850B1 (en) 2015-01-26 2025-04-16 Bausch & Lomb Incorporated Ophthalmic suspension composition
MX2017012062A (en) 2015-03-23 2018-06-18 Biopharmx Inc Pharmaceutical tetracycline composition for dermatological use.
US11103517B2 (en) 2015-04-07 2021-08-31 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions for minocycline
EA202091653A1 (en) * 2018-01-07 2020-12-23 Д-Р Редди'С Лабораторис Лтд. MINOCYCLINE FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES
CN111210890B (en) * 2020-02-14 2023-06-16 成都木老仁康软件信息有限公司 Anticoagulation pharmacy monitoring management method based on clinical data

Citations (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932615A (en) * 1973-03-16 1976-01-13 Meiji Seika Co., Ltd. Process for the preparation of granules
US3957980A (en) * 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
US3966922A (en) * 1971-07-23 1976-06-29 Takeda Chemical Industries, Ltd. Composition for poultry and livestock
US4086332A (en) * 1976-01-02 1978-04-25 Pfizer Inc. Doxycycline compositions
US4126680A (en) * 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4376118A (en) * 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
US4443442A (en) * 1979-12-21 1984-04-17 Skillern Scott D Method and composition for treatment of acne vulgaris
US4701320A (en) * 1984-11-29 1987-10-20 Lederle (Japan), Ltd. Composition stably containing minocycline for treating periodontal diseases
US4764377A (en) * 1983-10-07 1988-08-16 The Forsyth Dental Infirmary For Children Intra-pocket drug delivery devices for treatment of periodontal diseases
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4806529A (en) * 1982-11-18 1989-02-21 Trustees Of Tufts College, Tufts University Tetracycline activity enhancement
US4837030A (en) * 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
US4925833A (en) * 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US4935412A (en) * 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4960913A (en) * 1987-09-18 1990-10-02 Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt. Process for the preparation of pharmaceutical compositions
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5122519A (en) * 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
US5167964A (en) * 1992-02-14 1992-12-01 Warner-Lambert Company Semi-enteric drug delivery systems and methods for preparing same
US5188836A (en) * 1990-07-27 1993-02-23 Warner-Lambert Company Sustained release formulations
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5209978A (en) * 1985-12-26 1993-05-11 Taisho Pharmaceutical Co., Ltd. Seamless soft capsule and production thereof
US5211958A (en) * 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
US5217493A (en) * 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
US5230895A (en) * 1990-05-01 1993-07-27 Copley Pharmaceutical Inc. Sustained released delivery system for use in the periodontal pocket
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US5277916A (en) * 1988-02-01 1994-01-11 F. H. Faulding & Co., Ltd. Tetracycline dosage form
US5283065A (en) * 1989-09-21 1994-02-01 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5300304A (en) * 1989-09-21 1994-04-05 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US5459135A (en) * 1989-12-04 1995-10-17 The Research Foundation Of State University Of New York Composition comprising indomethacin [non-steroidal anti-inflammatory agent] and effectively non-antibacterial tetracycline to reduce bone loss
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5554654A (en) * 1986-12-23 1996-09-10 Tristrata Inc Method for enhancing the therapeutic effect of an anti-acne agent
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5665776A (en) * 1986-12-23 1997-09-09 Tristrata Technology, Inc. Additives enhancing topical actions of therapeutic agents
US5674539A (en) * 1994-12-09 1997-10-07 Tomas; Robert E. Method of treating skin and composition
US5776489A (en) * 1989-09-21 1998-07-07 American Cyanamid Company Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form
US5780049A (en) * 1991-10-16 1998-07-14 Richardson-Vicks Inc. Enhanced skin penetration system for improved topical delivery of drugs
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US5789395A (en) * 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5800836A (en) * 1992-08-05 1998-09-01 F. H. Faulding & Co. Limited Pelletized pharmaceutical composition
US5814331A (en) * 1995-11-13 1998-09-29 Holen; Sheldon Process for inhibiting pathogenic bacteria in the oral cavity and for binding peptide growth factors on surfaces
US5824343A (en) * 1989-08-28 1998-10-20 Pharmaceutical Delivery Systems Bioerodible polymers, compositions and therapeutic method
US5834450A (en) * 1994-02-17 1998-11-10 Pfizer Inc. 9- (substituted amino) -alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5855904A (en) * 1994-11-01 1999-01-05 Dong Kook Pharmaceutical Co., Ltd. Biodegradable sustained release preparation for treating periodontitis
US5908838A (en) * 1998-02-19 1999-06-01 Medics Pharmaceutical Corporation Method for the treatment of acne
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6015804A (en) * 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US6087382A (en) * 1999-03-17 2000-07-11 Bonner, Jr.; Ernest L. Method for treatment of reactive arthritis or bursitis
US6120803A (en) * 1997-08-11 2000-09-19 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
US6165513A (en) * 1997-06-11 2000-12-26 The Procter & Gamble Co. Film-coated tablet for improved upper gastrointestinal tract safety
US6165999A (en) * 1995-05-03 2000-12-26 Pfizer Inc Tetracycline derivatives
US6194000B1 (en) * 1995-10-19 2001-02-27 F.H. Faulding & Co., Limited Analgesic immediate and controlled release pharmaceutical composition
US6340475B2 (en) * 1997-06-06 2002-01-22 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6340476B1 (en) * 1999-04-06 2002-01-22 Armaquest, Inc. Pharmaceutical dosage form for pulsatile delivery of methylphenidate
US20020015731A1 (en) * 1999-12-23 2002-02-07 Appel Leah E. Hydrogel-Driven Drug Dosage Form
US20020044968A1 (en) * 1996-10-28 2002-04-18 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US6429204B1 (en) * 1997-01-15 2002-08-06 University Of Miami Method of inhibiting cancer growth
US6455583B1 (en) * 1998-05-08 2002-09-24 The University Of Miami Method for treating meibomian gland disease
US6497902B1 (en) * 1999-12-01 2002-12-24 The Regents Of The University Of Michigan Ionically crosslinked hydrogels with adjustable gelation time
US20030044446A1 (en) * 2001-08-16 2003-03-06 Mucoadhesive Erodible Drug Delivery Device For Controlled Admn. Of Pharmaceuticals & Other Acti Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US20030082120A1 (en) * 2001-10-26 2003-05-01 Milstein Harold J. Method for reducing systemic effects of aging, effects of aging on the skin, and incidence of skin damage from sun exposure using antibiotics of the tetracycline family
US20030130240A1 (en) * 2001-04-05 2003-07-10 Ashley Robert A. Methods of treating acne
US6638922B2 (en) * 1998-11-18 2003-10-28 Collagenex Pharmaceuticals Incorporated 4-dedimethylaminotetracycline derivatives
US20030229055A1 (en) * 2002-04-16 2003-12-11 Ashley Robert A. Methods of simultaneously treating ocular rosacea and acne rosacea
US6667060B1 (en) * 1999-03-31 2003-12-23 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
US20040115261A1 (en) * 2001-04-05 2004-06-17 Ashley Robert A. Controlled delivery of tetracycline compounds and tetracycline derivatives
US20040185105A1 (en) * 2001-10-25 2004-09-23 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20040228912A1 (en) * 2003-04-07 2004-11-18 Rong-Kun Chang Once daily formulations of tetracyclines
US6863830B1 (en) * 2003-08-21 2005-03-08 Biolab Services, Inc. Dual layer tablet, method of making and use thereof
US20050136107A1 (en) * 2003-12-22 2005-06-23 Patel Mahendra R. Extended release antibiotic composition
US6958161B2 (en) * 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
US20060293290A1 (en) * 2005-06-24 2006-12-28 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20080241235A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080241197A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline dosage forms for the treatment of acne
US20080241241A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080242642A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7541347B2 (en) * 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
US7544373B2 (en) * 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376172A (en) * 1982-02-01 1983-03-08 Cincinnati Milacron Inc. Closed loop control of compressible fluid addition to a mixture of such fluid and a liquid
ATE128959T1 (en) 1989-01-24 1995-10-15 Spi Polyols Inc CRYOPROTECTIVE CRYSTALLINE SORBITOL BEADS.
FI922107A0 (en) 1991-05-10 1992-05-08 Faulding F H & Co Ltd MICROCAPSULAR COMPOSITION OCH FOERFARANDE.
WO1993018755A1 (en) 1992-03-25 1993-09-30 Depomed Systems, Incorporated Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
KR100296413B1 (en) * 1998-04-01 2001-11-14 김선진 Sustained released tablet containing cefaclor
JP3888064B2 (en) * 2000-01-27 2007-02-28 田辺製薬株式会社 Sustained release preparation and production method thereof
WO2001070288A2 (en) * 2000-03-23 2001-09-27 Genetics Institute, Inc. Thermoreversible polymers for delivery and retention of osteoinductive proteins
ES2266499T3 (en) * 2001-04-05 2007-03-01 Collagenex Pharmaceuticals, Inc. DOXICICLINE FOR THE TREATMENT OF ACNE.
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
EP1558268A4 (en) 2002-09-17 2008-09-17 Univ New York METHOD FOR TREATING AGE ASSOCIATED MEMORY DISORDERS (AAMI), EASY COGNITIVE IMPAIRMENT (MCI), AND CELL CYCLIC DISEASES
JP4443834B2 (en) * 2003-01-24 2010-03-31 杏林製薬株式会社 Sustained release tablet and method for producing the same
WO2004078111A2 (en) 2003-03-06 2004-09-16 Ranbaxy Laboratories Limited Extended release minocycline compositions and processes for their preparation
JP2007510757A (en) 2003-11-06 2007-04-26 ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク How to treat eczema
GB2414668B (en) 2004-06-03 2009-07-29 Dexcel Ltd Tetracycline modified release delivery system

Patent Citations (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966922A (en) * 1971-07-23 1976-06-29 Takeda Chemical Industries, Ltd. Composition for poultry and livestock
US3957980A (en) * 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
US3932615A (en) * 1973-03-16 1976-01-13 Meiji Seika Co., Ltd. Process for the preparation of granules
US4086332A (en) * 1976-01-02 1978-04-25 Pfizer Inc. Doxycycline compositions
US4126680A (en) * 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
US4443442A (en) * 1979-12-21 1984-04-17 Skillern Scott D Method and composition for treatment of acne vulgaris
US4376118A (en) * 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4806529A (en) * 1982-11-18 1989-02-21 Trustees Of Tufts College, Tufts University Tetracycline activity enhancement
US4764377A (en) * 1983-10-07 1988-08-16 The Forsyth Dental Infirmary For Children Intra-pocket drug delivery devices for treatment of periodontal diseases
US4925833A (en) * 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US4935411A (en) * 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4935412A (en) * 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4701320A (en) * 1984-11-29 1987-10-20 Lederle (Japan), Ltd. Composition stably containing minocycline for treating periodontal diseases
US5209978A (en) * 1985-12-26 1993-05-11 Taisho Pharmaceutical Co., Ltd. Seamless soft capsule and production thereof
US5665776A (en) * 1986-12-23 1997-09-09 Tristrata Technology, Inc. Additives enhancing topical actions of therapeutic agents
US5554654A (en) * 1986-12-23 1996-09-10 Tristrata Inc Method for enhancing the therapeutic effect of an anti-acne agent
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4960913A (en) * 1987-09-18 1990-10-02 Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt. Process for the preparation of pharmaceutical compositions
US4837030A (en) * 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
US5211958A (en) * 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
US5277916A (en) * 1988-02-01 1994-01-11 F. H. Faulding & Co., Ltd. Tetracycline dosage form
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5122519A (en) * 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
US5824343A (en) * 1989-08-28 1998-10-20 Pharmaceutical Delivery Systems Bioerodible polymers, compositions and therapeutic method
US5283065A (en) * 1989-09-21 1994-02-01 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5300304A (en) * 1989-09-21 1994-04-05 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US5776489A (en) * 1989-09-21 1998-07-07 American Cyanamid Company Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form
US5413777A (en) * 1989-09-21 1995-05-09 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US5459135A (en) * 1989-12-04 1995-10-17 The Research Foundation Of State University Of New York Composition comprising indomethacin [non-steroidal anti-inflammatory agent] and effectively non-antibacterial tetracycline to reduce bone loss
US5230895A (en) * 1990-05-01 1993-07-27 Copley Pharmaceutical Inc. Sustained released delivery system for use in the periodontal pocket
US5188836A (en) * 1990-07-27 1993-02-23 Warner-Lambert Company Sustained release formulations
US5780049A (en) * 1991-10-16 1998-07-14 Richardson-Vicks Inc. Enhanced skin penetration system for improved topical delivery of drugs
US5167964A (en) * 1992-02-14 1992-12-01 Warner-Lambert Company Semi-enteric drug delivery systems and methods for preparing same
US5348748A (en) * 1992-03-02 1994-09-20 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US5217493A (en) * 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5800836A (en) * 1992-08-05 1998-09-01 F. H. Faulding & Co. Limited Pelletized pharmaceutical composition
US5834450A (en) * 1994-02-17 1998-11-10 Pfizer Inc. 9- (substituted amino) -alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5855904A (en) * 1994-11-01 1999-01-05 Dong Kook Pharmaceutical Co., Ltd. Biodegradable sustained release preparation for treating periodontitis
US5674539A (en) * 1994-12-09 1997-10-07 Tomas; Robert E. Method of treating skin and composition
US6165999A (en) * 1995-05-03 2000-12-26 Pfizer Inc Tetracycline derivatives
US6194000B1 (en) * 1995-10-19 2001-02-27 F.H. Faulding & Co., Limited Analgesic immediate and controlled release pharmaceutical composition
US5814331A (en) * 1995-11-13 1998-09-29 Holen; Sheldon Process for inhibiting pathogenic bacteria in the oral cavity and for binding peptide growth factors on surfaces
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US5789395A (en) * 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US20020044968A1 (en) * 1996-10-28 2002-04-18 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US6429204B1 (en) * 1997-01-15 2002-08-06 University Of Miami Method of inhibiting cancer growth
US6340475B2 (en) * 1997-06-06 2002-01-22 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6165513A (en) * 1997-06-11 2000-12-26 The Procter & Gamble Co. Film-coated tablet for improved upper gastrointestinal tract safety
US6120803A (en) * 1997-08-11 2000-09-19 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
US5908838A (en) * 1998-02-19 1999-06-01 Medics Pharmaceutical Corporation Method for the treatment of acne
US6455583B1 (en) * 1998-05-08 2002-09-24 The University Of Miami Method for treating meibomian gland disease
US6015804A (en) * 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US6638922B2 (en) * 1998-11-18 2003-10-28 Collagenex Pharmaceuticals Incorporated 4-dedimethylaminotetracycline derivatives
US20040002481A1 (en) * 1998-11-18 2004-01-01 Collagenex Pharmaceuticals, Inc. Novel 4-dedimethylaminotetracycline derivatives
US6087382A (en) * 1999-03-17 2000-07-11 Bonner, Jr.; Ernest L. Method for treatment of reactive arthritis or bursitis
US6667060B1 (en) * 1999-03-31 2003-12-23 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6340476B1 (en) * 1999-04-06 2002-01-22 Armaquest, Inc. Pharmaceutical dosage form for pulsatile delivery of methylphenidate
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
US6497902B1 (en) * 1999-12-01 2002-12-24 The Regents Of The University Of Michigan Ionically crosslinked hydrogels with adjustable gelation time
US20020015731A1 (en) * 1999-12-23 2002-02-07 Appel Leah E. Hydrogel-Driven Drug Dosage Form
US7211267B2 (en) * 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
US20030130240A1 (en) * 2001-04-05 2003-07-10 Ashley Robert A. Methods of treating acne
US20030139380A1 (en) * 2001-04-05 2003-07-24 Ashley Robert A. Use methods of treating acne and telangiectasia
US20040115261A1 (en) * 2001-04-05 2004-06-17 Ashley Robert A. Controlled delivery of tetracycline compounds and tetracycline derivatives
US20030044446A1 (en) * 2001-08-16 2003-03-06 Mucoadhesive Erodible Drug Delivery Device For Controlled Admn. Of Pharmaceuticals & Other Acti Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US7976870B2 (en) * 2001-10-25 2011-07-12 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20040185105A1 (en) * 2001-10-25 2004-09-23 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030082120A1 (en) * 2001-10-26 2003-05-01 Milstein Harold J. Method for reducing systemic effects of aging, effects of aging on the skin, and incidence of skin damage from sun exposure using antibiotics of the tetracycline family
US6958161B2 (en) * 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
US20030229055A1 (en) * 2002-04-16 2003-12-11 Ashley Robert A. Methods of simultaneously treating ocular rosacea and acne rosacea
US7008631B2 (en) * 2002-04-16 2006-03-07 Collagenex Pharmaceuticals, Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
US20040228912A1 (en) * 2003-04-07 2004-11-18 Rong-Kun Chang Once daily formulations of tetracyclines
US6863830B1 (en) * 2003-08-21 2005-03-08 Biolab Services, Inc. Dual layer tablet, method of making and use thereof
US20050136107A1 (en) * 2003-12-22 2005-06-23 Patel Mahendra R. Extended release antibiotic composition
US20060293290A1 (en) * 2005-06-24 2006-12-28 Medicis Pharmaceutical Corporation Method for the treatment of acne
US7790705B2 (en) * 2005-06-24 2010-09-07 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20070275933A1 (en) * 2005-06-24 2007-11-29 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20080070872A1 (en) * 2005-06-24 2008-03-20 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20070270390A1 (en) * 2005-06-24 2007-11-22 Medicis Pharmaceutical Corporation Method of the treament of acne
US20070259039A1 (en) * 2005-06-24 2007-11-08 Medicis Pharmaceutical Corporation Method for the treatment of acne
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20100330131A1 (en) * 2005-06-24 2010-12-30 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080241235A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7544373B2 (en) * 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7541347B2 (en) * 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
US20080242642A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080241241A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080241197A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline dosage forms for the treatment of acne

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080070872A1 (en) * 2005-06-24 2008-03-20 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20080182827A2 (en) * 2005-06-24 2008-07-31 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20090041846A1 (en) * 2005-06-24 2009-02-12 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7790705B2 (en) 2005-06-24 2010-09-07 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8268804B2 (en) 2005-06-24 2012-09-18 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US20080241241A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US9192615B2 (en) 2008-08-06 2015-11-24 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline

Also Published As

Publication number Publication date
AU2006262428B2 (en) 2012-02-23
US20080070872A1 (en) 2008-03-20
US20070259039A1 (en) 2007-11-08
NZ564093A (en) 2011-06-30
US20080182827A2 (en) 2008-07-31
CN101208097A (en) 2008-06-25
US20070270390A1 (en) 2007-11-22
ZA200802064B (en) 2009-09-30
CA2613273C (en) 2015-12-08
EP1898925A2 (en) 2008-03-19
IL188331A0 (en) 2008-08-07
EP1898925A4 (en) 2009-07-29
AU2006262428A1 (en) 2007-01-04
CA2613273A1 (en) 2007-01-04
US7919483B2 (en) 2011-04-05
JP5744976B2 (en) 2015-07-08
US20070225262A2 (en) 2007-09-27
JP2008543936A (en) 2008-12-04
US20080182825A2 (en) 2008-07-31
NO20080444L (en) 2008-01-23
WO2007001961A2 (en) 2007-01-04
WO2007001961A3 (en) 2007-05-18
US20080181945A2 (en) 2008-07-31
US20070275933A1 (en) 2007-11-29
JP2013213047A (en) 2013-10-17
US20060293290A1 (en) 2006-12-28
US20080182826A2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
CA2613273C (en) Method for the treatment of acne
US20220016041A1 (en) Once Daily Formulations Of Tetracyclines
KR102049253B1 (en) Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease
MXPA05001538A (en) Endoscope sleeve dispenser.
KR102479497B1 (en) Sustained release pharmaceutical formulation of varenicline and preparation method thereof
EP2241310A2 (en) Modified release formulations of emoxypine
KR20120033557A (en) Immediate-release and sustained-release pharmaceutical composition comprising levodropropizine
CZ301449B6 (en) Drug dosage form
US6100300A (en) Metformin formulations and method for treating intermittent claudication employing same
KR20200035437A (en) Pharmaceutical composition comprising Remogliflozin and diabetes treatment
US9308164B2 (en) Hyoscyamine dosage form
US20060198886A1 (en) Medicament having coated methenamine combined with acidifier
CN114401724B (en) Hypoglycemic pharmaceutical composition
US20170326065A1 (en) Methods and composition for treatment of cardiovascular conditions
WO2021053564A1 (en) Pharmaceutical composition comprising remogliflozin or salt or ester thereof and teneligliptin or salt thereof
US20170326066A1 (en) Method of treating hypertension
KR20210133495A (en) Pharmaceutical composition for preventing or treating periodontal disease which has improved convenience for internal use through size reduction for formulation comprising titrated extract of the unsaponifiable fraction of Zea Mays L. and extract of Magnoliae Cortex

Legal Events

Date Code Title Description
AS Assignment

Owner name: MEDICIS PHARMACEUTICAL CORPORATION, ARIZONA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WORTZMAN, MITCHELL;PLOTT, R. TODD;BHATIA, KULJIT;AND OTHERS;REEL/FRAME:019750/0144;SIGNING DATES FROM 20070817 TO 20070823

Owner name: MEDICIS PHARMACEUTICAL CORPORATION, ARIZONA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WORTZMAN, MITCHELL;PLOTT, R. TODD;BHATIA, KULJIT;AND OTHERS;SIGNING DATES FROM 20070817 TO 20070823;REEL/FRAME:019750/0144

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION